Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.

Literature DB >> 22158473

Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.

Abstract

Understanding the complex interactions between the various pathways disrupted in polycystic kidney and liver disease is essential to identify and optimize therapies for these disorders. Studies published in the past year have demonstrated a functional interaction between the main proteins implicated in these diseases and identified novel therapeutic approaches.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
TRPP Cation Channels

Year: 2011 PMID： 22158473 PMCID： PMC4096714 DOI： 10.1038/nrneph.2011.196

Source DB: PubMed Journal: Nat Rev Nephrol ISSN： 1759-5061 Impact factor: 28.314

10 in total

1. Polycystin-1 regulates STAT activity by a dual mechanism.

Authors: Jeffrey J Talbot; Jonathan M Shillingford; Shivakumar Vasanth; Nicholas Doerr; Sambuddho Mukherjee; Mike T Kinter; Terry Watnick; Thomas Weimbs
Journal: Proc Natl Acad Sci U S A Date: 2011-04-25 Impact factor: 11.205

2. Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Authors: Gail A Reif; Tamio Yamaguchi; Emily Nivens; Hiroyuki Fujiki; Cibele S Pinto; Darren P Wallace
Journal: Am J Physiol Renal Physiol Date: 2011-08-03

3. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.

Authors: Wouter N Leonhard; Annemieke van der Wal; Zlata Novalic; Steven J Kunnen; Ron T Gansevoort; Martijn H Breuning; Emile de Heer; Dorien J M Peters
Journal: Am J Physiol Renal Physiol Date: 2011-02-23

4. Macrophages promote cyst growth in polycystic kidney disease.

Authors: Anil Karihaloo; Farrukh Koraishy; Sarah C Huen; Yashang Lee; David Merrick; Michael J Caplan; Stefan Somlo; Lloyd G Cantley
Journal: J Am Soc Nephrol Date: 2011-09-15 Impact factor: 10.121

5. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.

Authors: Vinita Takiar; Saori Nishio; Patricia Seo-Mayer; J Darwin King; Hui Li; Li Zhang; Anil Karihaloo; Kenneth R Hallows; Stefan Somlo; Michael J Caplan
Journal: Proc Natl Acad Sci U S A Date: 2011-01-24 Impact factor: 11.205

6. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

Authors: Ayumi Takakura; Erik A Nelson; Nadeem Haque; Benjamin D Humphreys; Kambiz Zandi-Nejad; David A Frank; Jing Zhou
Journal: Hum Mol Genet Date: 2011-08-05 Impact factor: 6.150

7. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.

Authors: Sorin V Fedeles; Xin Tian; Anna-Rachel Gallagher; Michihiro Mitobe; Saori Nishio; Seung Hun Lee; Yiqiang Cai; Lin Geng; Craig M Crews; Stefan Somlo
Journal: Nat Genet Date: 2011-06-19 Impact factor: 38.330

8. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Authors: Eiji Higashihara; Vicente E Torres; Arlene B Chapman; Jared J Grantham; Kyongtae Bae; Terry J Watnick; Shigeo Horie; Kikuo Nutahara; John Ouyang; Holly B Krasa; Frank S Czerwiec
Journal: Clin J Am Soc Nephrol Date: 2011-09-08 Impact factor: 8.237

9. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors: Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao
Journal: Am J Physiol Renal Physiol Date: 2010-12-08

10. Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Authors: Bonnie L Blazer-Yost; Julie Haydon; Tracy Eggleston-Gulyas; Jey-Hsin Chen; Xiaofang Wang; Vincent Gattone; Vicente E Torres
Journal: PPAR Res Date: 2010-11-01 Impact factor: 4.964

10 in total

18 in total

Review 1. Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors: Gustavo Blanco; Darren P Wallace
Journal: Am J Physiol Renal Physiol Date: 2013-06-12

2. Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease.

Authors: Erin E Olsan; Jonathan D West; Jacob A Torres; Nicholas Doerr; Thomas Weimbs
Journal: Am J Physiol Renal Physiol Date: 2018-03-07

3. Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease.

Authors: Erin E Olsan; Tamami Matsushita; Mina Rezaei; Thomas Weimbs
Journal: J Biol Chem Date: 2015-04-28 Impact factor: 5.157

4. Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca²⁺]_i homeostasis in human autosomal-dominant polycystic kidney disease cells.

Authors: Viktor Tomilin; Gail A Reif; Oleg Zaika; Darren P Wallace; Oleh Pochynyuk
Journal: FASEB J Date: 2018-03-19 Impact factor: 5.191

5. Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease.

Authors: Carolina I Galarreta; Jared J Grantham; Michael S Forbes; Robin L Maser; Darren P Wallace; Robert L Chevalier
Journal: Am J Pathol Date: 2014-05-09 Impact factor: 4.307

Review 6. The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors: Jared J Grantham; Vicente E Torres
Journal: Nat Rev Nephrol Date: 2016-10-03 Impact factor: 28.314

Review 7. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.

Authors: Robert L Chevalier
Journal: Am J Physiol Renal Physiol Date: 2016-05-18